Kymera Therapeutics (KYMR) Conference February 06, 2025 10:00 AM ET Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Conference Call Participants Michael Schmidt - Senior Managing Director & Equity Research Analyst - Biotechnology Michael Schmidt Michael Schmidt, senior biotic analyst with Guggenheim, and I'd like to welcome, Nelo Manolfi, the founder, president, and CEO of Chimera to this next fireside chat. Nelo, welcome and thanks for joining us. Nello Mainolfi Thanks, Michael, ...

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim SMID Cap Biotechnology Conference in New York, NY on February 6 at 10:00 a.m. ET; andOppenheimer 35th Annual Healthcare Life Scienc ...

Core Insights - Kymera Therapeutics, Inc. (KYMR) announced its business goals for 2025, focusing on its immunology pipeline, leading to an 8% increase in stock price and a 47.2% rise over the past year compared to a 16% decline in the industry [1] Pipeline Updates - Kymera is developing KT-621, a first-in-class oral degrader of STAT6, showing dupilumab-like activity and strong safety data in preclinical models [2] - Recruitment is ongoing for a phase I study of KT-621, which has potential applications in various Th2 diseases, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease [3] - Kymera plans to complete the phase I study and report data in Q2 2025, with a phase lb study in atopic dermatitis also set for Q2 2025 and a phase IIb study planned for Q4 2025 [4] Additional Candidates - Kymera is evaluating KT-295, a first-in-class oral degrader of TYK2, with plans to file an investigational new drug application and initiate a phase I study in Q2 2025, expecting data in Q4 2025 [5] - KT-474 (SAR444656), an IRAK4 degrader, is in development for immune-inflammatory diseases, with Sanofi planning to expand ongoing mid-stage studies toward pivotal studies following positive preliminary data [6][7] - Kymera and Sanofi aim to advance KT-474 in phase IIb studies for hidradenitis suppurativa and atopic dermatitis, with primary completion expected in 2026 [8] Future Developments - Kymera plans to announce a new immunology program targeting an undrugged transcription factor in H1 2025, with clinical testing expected in early 2026 [10] - The company decided not to continue developing KT-333 and KT-253 beyond phase I due to a strategic focus on its immunology pipeline [10] Financial Position - As of December 31, 2024, Kymera had an estimated $850 million in cash, sufficient to fund operations into mid-2027 [11]

Kymera Therapeutics, Inc. (KYMR) shares rallied 7.8% in the last trading session to close at $40.12. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.6% loss over the past four weeks.Shares gained as investors were impressed by the pipeline updates provided by the company at the J.P. Morgan Annual Healthcare Conference. Kymera has a sound cash position and ended 2024 with an estimated cash of $850 million, ...

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and plans to initiate parallel Phase 2b trials in AD and asthma in late 2025 and early 2026, respectively KT-295 (TYK2) to advance into Phase 1 testing in 2Q25 with data expected in late 2025 KT-474/SAR444656 (IRAK4) Phase 2b dose-ranging studies in hidradenitis suppurativa (HS) and AD ongoing, with completion expect ...

WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will provide an ...

WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Piper Sandler 36th Annual Healthcare Conference in New York, NY on December 3 at 1:00 p.m. ET; and7th Annual Evercore ISI HealthCONx Conference in Coral Gables, FL on Decem ...

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA on November 12 at 10:00 a.m. ET;J.P. Morgan Equity Opportunities Forum in Miami, FL on November 14, one- ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President & CEO Jared Gollob - Chief Medical Officer Bruce Jacobs - CFO Conference Call Participants Marc Frahm - TD Cowen Kalpit Patel - B. Riley Alexei Siniakov - Truist Securities Brad Canino - Stifel Nicolaus Gospel Enyindah-Asonye - Morgan Stanley Kelly Shi - Jefferies Jeff Jones - Oppenheimer Eric Joseph - J.P. Morgan Michael S ...

Kymera Therapeutics, Inc. (KYMR) reported a loss of 82 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 83 cents. In the year-ago quarter, Kymera reported a loss of 90 cents per share.Collaboration revenues totaled $3.7 million, which missed the Zacks Consensus Estimate of $9 million. The reported figure increased 20.8% from the year-ago level.Collaboration revenues in the third quarter were mostly earned due to the company’s association with bigwig Sanof ...